Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
NIAID researchers developed a recombinant HIV-1 trimer immunogen that utilizes a closed conformation of trimeric gp120 to stabilize epitopes for broadly neutralizing antibodies. The recombinant Env ectodomain trimers can induce higher neutralizing antibody titers than wild type Env trimers.
NIAID researchers have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.
The development of monoclonal antibodies (MAbs) against norovirus virus-like particles (VLPs) has allowed the identification and characterization of key antigenic sites of the virus capsid and facilitated the development of diagnostic assays.
35O22 is a potent anti-HIV antibody that binds a novel HIV epitope. This antibody neutralizes at least 80% of HIV isolates tested so far. The unique binding of 35O22 makes it an attractive candidate to combine with other HIV antibodies or antivirals in treating or preventing HIV infection.
Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy.
Attracting the interest of large biopharma companies, the crescendo Biologics Humabody platform and product candidates are targeting immuno-oncology and beyond.
BIOCAD, the leading Russian biotechnology company, owns a robust portfolio of globally marketed products and is focusing its efforts on research and development of novel compounds and biologics, primarily for oncology. Building on its national leadership position, the company is seeking to expand its international presence through joint clinical development partnerships.
By using a tissue-specific hormone inhibitor to rebalance local estrogen metabolism, Forendo Pharma could provide long-term treatment to millions of women suffering from endometriosis.
YUMAB, a global provider of fully human monoclonal antibodies, offers ultra-fast discovery and efficient lead development. The company is looking to expand its network of collaborators and clients through flexible licensing options for diagnostics and therapeutics development, as well as the provision of customized fee-for-service solutions.
BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments.
BioEclipse (formerly ConcentRx) is preparing to start clinical trials of its novel approach to immuno-oncology, which combines two monotherapies with a synergistic effect.
Providing ultra-high-throughput screening of single cell assays and antibody-producing cells as well as the ability to sort them, Cyto-Mine is ready for use.
By leveraging its unique and versatile production-platform technology, Glycostem has developed highly pure and active cancer-fighting cell therapy products that are safe and effective for allogeneic transplantation in patients with hematological cancers and solid tumors.
Working with two complementary technologies, biotech company MicroQuin is developing next-generation targeted therapies that kill all breast cancers with no toxicity.
BerGenBio, a Norwegian biotech, is developing an oral, once-a-day Axl inhibitor that shows promise in treating aggressive cancers and in boosting the efficacy of checkpoint inhibitors.